NTrans Technologies today announced it has been awarded a prestigious, €1.5M EU SME instrument grant.
NTrans Technologies is a spin-off company that emerged from research of the Hubrecht Institute. The company is based on a proprietary technology (iTOP), which allows the intracellular delivery of therapeutic proteins in a wide range of cell types and tissues.
Marco de Boer, CEO of NTrans Technologies BV, commented: “We are honored that the European Commission recognized the tremendous potential of our iTOP Technology delivery platform”.
Supported by the 1.5 million euro SME instrument grant funding, NTrans Technologies will have the opportunity to further develop and market its iTOP Technology for research applications, and by this accelerate the growth of the company.
About SME instrument grant
The SME instrument grant is part of Horizon 2020, which is the largest EU Research and Innovation program ever.Provided with about €3 billion in funding over the period 2014-2020, the SME Instrument helps high-potential SMEs to develop groundbreaking innovative ideas for products, services or processes that are ready to face global market competition.
For more information, please visit:
Dr. Marco de Boer MBA